Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
When John Ebers, a commercial beekeeper in Comstock Park, Mich., was diagnosed with Stage 3 colorectal cancer, he was not given the option of genetic testing, which could have revealed if there were drugs that could attack his cancer.
Login
